Introduction
The Hedgehog (Hh) cell-cell signaling pathway is conserved in animals and has critical roles in embryonic development. Hedgehog proteins are secreted morphogens that are involved in many biological processes during embryonic development, and dysregulation of the pathway leads to several human diseases. It is expressed in many tissues, especially those of the brain and limbs. Hh signaling organizes pattern formation in the embryonic limbs, neural tube and other structures, and also functions postembryonically in homeostatic processes such as tissue maintenance and regeneration [1] . In the resting state of Hh signaling, the transcriptional output of the pathway is held back by the membrane protein Patched (Ptc), which inhibits the seven-spanner Smoothened (Smo). The Hh pathway is activated when the secreted protein Hh binds and inactivates Ptc, thus relieving the inhibition exerted on Smo, rendering it active.
Active Smo signals to the cytoplasm, leading to activation of the zinc finger transcription factors, the Gli proteins (Gli1, 2 and 3) in vertebrates [2] .
Gli1 and Gli2 act primarily as transcriptional activators, and Gli2 is the primary activator of Hh target genes in neural tube patterning [3] . Gli3 can act as either a transcriptional activator or, if proteolytically processed, as a transcriptional repressor that keeps target genes inactive in the absence of ligand. Hh activity promotes transcriptional activation of target genes in two ways: it promotes formation of Gli activators and it blocks the proteolytic processing event that creates the Gli3 repressor.
Shh is required for normal patterning of the limbs, where it regulates growth, digit number, and antero-posterior polarity [4] .
Maturation of Hh protein needs the posttranslational addition of palmitate and cholesterol which both play a role in protein activity. Cholesterol level may be decreased in several instances. Its level has been reported to be low in at least two congenital defects: trisomy 18
and Smith-Lemli-Opitz syndrome [5, 6] .
Trisomy 18 is one of the most frequent aneuploidies found in 1/8 000 births. Presence of an extra chromosome 18 is responsible for a polymalformative syndrome in which facial anomalies such as microcephaly, dolichocephaly, cleft palate, congenital heart defects and limb anomalies may be found [7] .
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive syndrome characterized by multiple congenital anomalies (craniofacial, limb), intellectual deficit and behavioral problems. SLOS is due to an inborn error of cholesterol synthesis and is caused by mutations in the DHCR7 gene (11q13.4) leading to a deficiency in the enzyme 3-beta-hydroxysteroldelta7 reductase that converts 7-dehydrocholesterol to cholesterol [8] .
Both affections are characterized by an extremely low level of unconjugated estriol [3] measured in maternal serum during the 2 nd trimester of pregnancy, and it has been reported that individuals with either of these syndromes exhibit low cholesterolemia.
The aim of this study is to determine whether a cholesterol deficit may be responsible for phenotypic anomalies observed in these two syndromes that depend on the Shh pathway, i.e.
craniofacial and limb anomalies. We studied cholesterol levels and the Shh pathway in 14 cultures of trisomic 18 amniocytes and 3 cultures of SLO amniocytes.
Materials and methods

Materials
Among our cases of prenatal diagnoses, 12 cases of trisomy 18 and 3 cases of SLO were selected. Fetopathological examination was recorded for each case, and malformations were reported in Table I . The number of malformations was compared to maternal uE 3 levels and 3 controls per trisomy 18 were chosen according to their term.
Amniocytes from these 60 cases were grown in RPMI® medium.
Liquid chromatography associated with tandem mass spectrometry (LC/MSMS)
There is only a tiny amount of cholesterol in the amniocyte culture medium, and the cholesterol originated by efflux from amniocytes is at very low level, so its dosage is impossible using biochemical or CPG/SM methods. It is only accessible using a more sensitive technique, liquid chromatography associated with tandem mass spectrometry (LC/MSMS) as a measurement technique LC/MSMS.
A range of cholesterol levels was established in the culture medium (RPMI®) (6 concentrations ranging from 0 to 50 µg/mL) to perform a comparative quantitative dosage.
For each cell culture, the protein digests from both plasma and serum lipoprotein fractions were analyzed on an ion trap mass spectrometer interfaced with an autosampler through which samples were loaded onto a C 18 capillary column (100 × 0.1 mm). 
Cholesterol levels in culture flasks
Cholesterol levels were related to the amount of protein contained in flasks, made possible using the Bradford protein assay. It was expressed in µg/mL/g of protein and was performed for the 60 cultures.
RNA isolation and real-time RT-PCR analysis
Total RNA from the amniocyte cultures was extracted using Trizol (Invitrogen by Fisher Bioblock Scientific, Illkirch, France). After extraction, 1 μg of DNase-I-treated RNA was reverse transcribed into cDNA in the presence of oligodT and Moloney murine leukemia virus reverse transcriptase (Invitrogen). The reaction was carried out at 37°C for 1 h followed by a further 10-min step at 95°C. Amplification of the generated cDNA was performed by realtime PCR in an Applied Biosystems SDS7000 apparatus with appropriate primers designed using Primer Express software. The relative mRNA level was calculated with the 2 −ΔΔCT method.
The following Shh pathway gene expressions were analyzed with this method: transcription factors GLI1, GLI2 and GLI3, and target genes expressed in facial and skeletal bone formation BMP2, BMP4, TGFß1 and collagen type I genes COL1A1 and COL1A2. Their expression was compared to GAPDH expression.
Western blot analysis
In order to confirm Shh pathway alteration, we performed Western blot analysis in trisomy 18 amniocytes compared to control amniocytes for Shh proteins BMP2 and COL1A1. They were all compared with GAPDH expression.
Treatment of control amniocytes with HMG-CoA reductase inhibitor
Control amniocytes were treated with an inhibitor of HMG-CoA reductase (atorvastatin®) in order to deplete cholesterol levels in the amniocyte culture medium to the same level observed in trisomy 18 and SLO.
Treatment was performed with 50 µL of 100 µM atorvastatin®. Culture medium was collected on day 1, day 2 and day3 after treatment. This allowed us to obtain a cholesterol level as low as that observed in the culture medium of trisomy 18 amniocytes.
Results
Inverse correlation between maternal uE 3 levels and phenotypic severity in fetuses with SLO or trisomy 18.
We observed that decreased maternal uE 3 level was associated with a higher number of malformations observed in 12 fetuses exhibiting trisomy 18 and 3 fetuses with SLO. The mean number of malformations was significantly (p = 0.02) higher (5.1) when uE 3 was below 0.35 MoM than when it was higher (3.1 malformations).
Facial/cerebral anomalies were more frequent when uE 3 
Cholesterol level is significantly decreased in trisomy 18 and SLO amniocytes compared to control amniocytes
We analyzed the cholesterol level in relation to term of pregnancy and found no significant difference throughout pregnancy, indicating that this concentration is valid independent of pregnancy term. Mean cholesterol level for each group (SLO, trisomy 18 and control) is reported in Figure 3 . We observed that cholesterol level in culture medium is significantly higher (p<0.05 and p<0.01 respectively) in controls (15.21 µg/mL/g) than in cases of trisomy 18 (11.54 µg/mL/g) and SLO (6.52 µg/mL/g).
Sonic Hedgehog pathway is altered in trisomy 18 and SLO amniocytes
We reported an alteration in the Shh pathway using 2 different approaches.
Comparative expression of different target genes in the Sonic Hedgehog pathway is shown in Figure 4 . We observed that all Gli transcription factors have decreased expression in trisomy 18 and SLO amniocytes compared to control amniocytes. Gli3 is specifically decreased in trisomy 18 amniocytes, whereas Gli1 is predominantly decreased in SLO amniocytes.
Target gene expression of the Sonic Hedgehog pathway is significantly decreased in trisomy 18 amniocytes compared to control amniocytes. Results are shown in Table II .
Western blot analysis
Western blot analysis in trisomy 18 amniocytes compared to control amniocytes for proteins Shh, BMP2 and COL1A1 confirmed decreased expression of these proteins in trisomy 18 amniocytes ( Figure 5 ).
Cholesterol defects alone, induced by treatment, does not alter Shh pathway as observed in trisomy 18 and SLO
After treating control amniocytes with an inhibitor of cholesterol synthesis, we tested these cells for alterations in the Shh pathway by performing RT-PCR analysis of the previously tested genes. Tests showed a trend towards decreased expression of these genes in treated amniocytes, but it was not as low as that observed in trisomy 18 or SLO amniocytes ( Figure   6 ).
Discussion
Maternal uE 3 level is measured during the second trimester of pregnancy for trisomy 21
screening. It is not only decreased in this affection, but also when fetuses carry trisomy 18 [10] or Smith-Lemli-Opitz syndrome [9, 11] . In our study, we observed an inverse correlation between maternal uE 3 levels and phenotypic severity, with fetuses exhibiting SLO, as Kratz (1999) and Tint reported [12, 13] . However, these findings also correlated with trisomy 18, as a low uE 3 level was associated with fetuses exhibiting significantly more clinical findings after fetopathological examination. Therefore, phenotypic abnormalities seem to be more severe when the maternal uE 3 level is below 0.35 MoM.
The uE 3 level is known to reflect fetal cholesterol biosynthesis. The association between SLO phenotypic severity and cholesterolemia has already been reported where severity is correlated to 7-DHCR residual activity [12] . However, this has never been described in T18 pregnancies. It is well known that hypocholesterolemia is found in Smith-Lemli-Opitz syndrome due to an enzymatic defect in the cholesterol biosynthesis pathway (7-DHCR) [14] .
Hypocholesterolemia is also present in rare cases of living trisomic 18 patients [11] .
Unfortunately, no enzymatic defect has been reported in this aneuploidy, but 7-DHC level is low, indicating a possible block upstream. It would be of interest to establish a sterol profile in the case of trisomy 18 in order to determine a possible enzymatic block in cholesterol synthesis. In the different syndromes associated with an enzymatic defect in cholesterol biosynthesis, low cholesterol level alone is not sufficient to explain all the malformations observed. However, the possible toxic role of a precursor accumulation has been discussed [15] .
Maternal apolipoprotein E (apoE) genotype also plays a role, as these apolipoproteins are involved in materno-fetal cholesterol transport [16] , with maternal homozygous apoE2 associated with more severely affected fetuses. Indeed, cholesterol intake from the mother may lower phenotypic severity.
We analyzed the cholesterol level in an amniocyte culture medium, a study that has not yet been reported. It reflects the cellular cholesterol level released by efflux [17] . The amount of cholesterol is tiny, making it impossible to measure using automated biochemistry. We thus performed measurements using an assay technique with better sensitivity, i.e. LC/MSMS, allowing cholesterol detection at very low levels and unaffected by culture medium and color.
We observed a disturbance in cholesterol biosynthesis in trisomic 18 amniocytes, which correlates with the uE 3 level measured in maternal serum. This cholesterol level is lowered by 30% in the cases of trisomy 18 and 60% in the cases of SLO, reflecting the more severe hypocholesterolemia observed in the cases of SLO. This difference may originate from a supply from another enzymatic pathway or more efficient materno-fetal cholesterol transport. A significant decrease in cholesterol level in amniocyte culture medium is associated with low maternal uE 3 and reflects a disturbance in the fetal cholesterol biosynthesis pathway.
The association of both cerebrofacial and limb abnormalities correlates to the maternal uE 3 level. Moreover, we showed that limb abnormalities were constant among patients with uE 3 <0.35 MoM. We thus may hypothesize that there is an impact of this cholesterol disturbance on these tissues. However, their embryogenesis depends highly on the Shh pathway which needs cholesterol for its maturation. Thus it is not surprising to observe these malformations as Shh expression is predominant in notochord, brain, ZPA and bowel [18] .
The link between Hh signaling and cholesterol is well established, as posttranslational addition of cholesterol plays a fundamental role in Shh maturation, where it helps to define the maximal activity of this morphogen due to liposolubility. However, the mechanisms of signal disruption are still insufficiently understood and there are contradictions regarding the role of cholesterol in long range signaling, where cholesterol can play an essential role [19] or can be unnecessary [20, 21] . We thus sought to assess the role of an altered Shh pathway in the pathogenicity of trisomy 18 and SLO, since many genes are Shh pathway targets, among them genes involved in brain and limb embryogenesis.
We demonstrated a decrease in all Gli transcription factor expression, as reported by Gofflot [22] in a SLO animal model treated with a DHCR7 inhibitor, AY-9944, which showed a significant decrease in Shh pathway target genes. Similarly, we reported a significant decrease in BMP2 expression, underlining a direct link between Shh and BMP2, but without a significant decrease in BMP4 expression, which is preferentially involved in dorso-ventral limb patterning and not directly linked to Shh [23] . Gofflot et al. also described an imbalance in Ihh expression in the forming cartilage of a rat model treated with triparanol, an inhibitor of the 24-dehydrocholesterol reductase, leading to syndactyly, with Bmp2 participating to the programmed cell death in digit formation [24] . We also reported a decreased expression of more downstream genes, such as type 1 collagen. This was expected since this collagen type is a target of BMP2 and TGFβ1. Type 1 collagen is a fibril-forming collagen found in most connective tissues which is abundant in bone, cornea, dermis and tendon. Its role in embryogenesis is predominant in bone formation and palatal fusion [25] , and we may hypothesize that an alteration in its expression may participate to the occurrence of cleft palate which exists in our 3 SLO cases and 2 out of our 14 T18 cases. TGFβ1 expression, an important proliferation factor, was also decreased, which may in part explain in utero growth retardation, present in our 3 SLO cases and 4 out of our 14 T18 cases. In addition, limb shortness seems to be associated with deficiency in cholesterol biosynthesis during embryonic development.
We tested whether this pathway alteration was associated with cholesterol deficit by treating normal amniocytes with an inhibitor of cholesterol synthesis (Atorvastatin) and testing gene expression of previously altered genes. Treatment led to a decrease of the same magnitude as that observed in trisomy 18 and SLO. However, despite a trend towards decreased expression, it was not significant. We may hypothesize that this lack of treatment impact may either be Finally, we demonstrated Shh pathway alteration in both trisomy 18 and SLO amniocytes using different approaches. This alteration may in part be due to a cholesterol defect, but other events are involved in this disturbance, and need to be explored. Table 1 .
Number of malformations observed in 12 cases of trisomy 18 (white) and 3 cases of SLO (gray) after fetopathological examination.
NTD: neural tube defect, CHD: congenital heart defect, VSD: ventricular septal defect, malf: malformations MoM: multiple of median.
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TGFβ1
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T18 ( Table II Comparative expression of Gli transcription factors and Shh target genes in trisomy 18 (n : 10) and SLO (n : 3) cases compared to 8 control cases. NA : not available Cholesterol/protein ratios were compared to maternal uE 3 levels measured during pregnancy in the 3 different groups analyzed (control, trisomy 18 and SLO cases). There is a correlation between cholesterol/protein ratios measured in amniocytes culture medium compared to maternal uE 3 level. This trend is indicated through the black line (parametric Pearson's test, p<0.05).
Figure 3
Cholesterol/protein ratios in the 3 different groups: control group (n=45), trisomy 18 group (n=12) and SLO (n=3). This ratio is expressed in µg/mL/g protein.
It is significantly decreased in T18 and SLO groups, compared to control group. Statistical significance was evaluated using the Student's t-test (* :p<0.05) Comparative expression of different Shh pathway genes in T18 and SLO amniocytes, compared to control amniocytes. The expression is in arbitrary units with GAPDH as reference gene (1) . Total RNAs were extracted from amniocytes and 1 µg was reverse-transcribed into cDNA. The resulting products were diluted (1/100) and analyzed by real-time PCR using specific primers for GLI1, GLI2, GLI3, TGFβ1, COL1A1, COL1A2, BMP2 and BMP4. Results were normalized to GAPDH cDNA. The expression shown is the average of 3 experiments. 8 control cases, 10 trisomy 18 cases and 3 SLO cases were analyzed. Statistical significance was evaluated using Student's t-test (* : p<0.05 ; ** : p<0.01 ; *** : p<0.001) Fig. 5 .
SHH, BMP2 and COL1A1 expressions are decreased in T18 amniocytes compared to control amniocytes.
15 μg of nuclear extracts from T18 or control amniocytes was separated on a 10% polyacrylamide gel in denaturing conditions. Then, proteins were transferred to a PVDF membrane and immuno-blotted with polyclonal antibodies directed against SHH (A, B), BMP2 (C, D) and COL1A1 (E) and GAPDH as loading control. After washing with TBS-T, PVDF membranes were incubated with the appropriate secondary antibody and proteins were revealed with the super signal West-Pico® detection kit.
Figure 6
Comparative expression of different Shh pathway's genes in control amniocytes, after 3 (D3) or 6 days (D6) of treatment with an anti-cholesterol. The expression isin arbitrary unit with GAPDH as reference gene (1) . Total RNAs were extracted from amniocytes and 1 µg was reverse-transcribed into cDNA. The resulting products were diluted (1/100) and analyzed by real-time PCR using specific primers for GLI1, GLI2, GLI3, TGFβ1, COL1A1, COL1A2, BMP2 and BMP4. Results were normalized to GAPDH cDNA without treatment. The expression shown is the average of 3 experiments. We analyzed 3 cases at D3, and 5 cases at D6. Statistical significance was evaluated using the Student's t-test (* : p<0.05 ; ** : p<0.01 ; *** : p<0.001)
